Literature DB >> 16737803

Investigation of the pronounced synergism between prostaglandin E2 and other constrictor agents on rat femoral artery.

Gloria H Y Hung1, Robert Leslie Jones, Francis F Y Lam, Kam-Ming Chan, Hiroyoshi Hidaka, Masaaki Suzuki, Yasuharu Sasaki.   

Abstract

This study investigates the pronounced synergism between the weak contractile action of prostaglandin E(2) (PGE(2)) and strong actions of phenylephrine, U-46619 and K(+) on rat isolated femoral artery. The potency ranking for synergism was SC-46275 (prostanoid receptor agonist selectivity: EP(3)>>EP(1))=sulprostone (EP(3)>EP(1))>17-phenyl PGE(2) (EP(1)>EP(3)). The novel EP(3) antagonist L-798106 (0.2-1microM) blocked the enhanced action of sulprostone (pA(2)=7.35-8.10), while the EP(1) antagonist SC-51322 (1microM) did not (pA(2)<6.0). Matching responses to priming agent and priming agent/sulprostone were similarly suppressed by nifedipine (300nM) and the selective Rho-kinase inhibitors H-1152 (0.1-1microM) and Y-27632 (1-10microM). Our findings implicate an EP(3) receptor in the prostanoid component of contractile synergism. While the synergism predominantly operates through a Ca(2+) influx-Rho-kinase pathway, the EP(3) receptor does not necessarily transduce via Rho-kinase.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16737803     DOI: 10.1016/j.plefa.2006.04.002

Source DB:  PubMed          Journal:  Prostaglandins Leukot Essent Fatty Acids        ISSN: 0952-3278            Impact factor:   4.006


  7 in total

1.  The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

2.  Investigation of the prostacyclin (IP) receptor antagonist RO1138452 on isolated blood vessel and platelet preparations.

Authors:  R L Jones; H Wise; R Clark; R L Whiting; K R Bley
Journal:  Br J Pharmacol       Date:  2006-07-31       Impact factor: 8.739

3.  Differential reactivity of human mammary artery and saphenous vein to prostaglandin E(2) : implication for cardiovascular grafts.

Authors:  N Foudi; L Kotelevets; I Gomez; L Louedec; D Longrois; E Chastre; X Norel
Journal:  Br J Pharmacol       Date:  2011-06       Impact factor: 8.739

Review 4.  Therapeutic implications of the prostaglandin pathway in Alzheimer's disease.

Authors:  Eiron Cudaback; Nikolas L Jorstad; Yue Yang; Thomas J Montine; C Dirk Keene
Journal:  Biochem Pharmacol       Date:  2014-01-13       Impact factor: 5.858

Review 5.  Prostanoid receptor antagonists: development strategies and therapeutic applications.

Authors:  R L Jones; M A Giembycz; D F Woodward
Journal:  Br J Pharmacol       Date:  2009-07-15       Impact factor: 8.739

6.  Regulation of arterial reactivity by concurrent signaling through the E-prostanoid receptor 3 and angiotensin receptor 1.

Authors:  Maria P Kraemer; Hyehun Choi; Jeff Reese; Fred S Lamb; Richard M Breyer
Journal:  Vascul Pharmacol       Date:  2016-05-31       Impact factor: 5.773

7.  Anti-inflammatory activity of ghrelin in human carotid artery cells.

Authors:  Kevin B S Chow; Christopher H K Cheng; Helen Wise
Journal:  Inflammation       Date:  2009-12       Impact factor: 4.092

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.